Obesity study: Semaglutide
Official title Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
ClinicalTrials.gov ID: NCT06396416
What this study is testing
What is Semaglutide?
An investigational once‑weekly injectable medicine being studied for weight loss in people with obesity and advanced kidney disease who want a transplant. It is designed to activate GLP‑1 receptors, which can reduce appetite and lower blood sugar.
Also referred to as GLP‑1RA, Ozempic, Wegovy.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find out if a virtual weight management program helps people with obesity and kidney disease lose weight to become eligible for a kidney transplant.
- Who it's for
- The study is looking for people with obesity and advanced kidney disease or those on dialysis who are hoping to get a kidney transplant.
- What's involved
- Participants will be assigned to either join a virtual weight management program or continue with their standard medical care.
- Time commitment
- The source text does not specify the duration of the study or the required visit schedule.
- Phase 4: studies an already-approved treatment
- Time commitment: about 26 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults aged 18 years or older
- BMI; 35 kg/m\^2
- 10% risk of ESKD requiring renal replacement therapy over 2 years or receiving dialysis
You likely can't join if
- Known contraindication to a GLP-1RA (pancreatitis, personal or family history of medullary thyroid cancer, hypersensitivity)
- Type 1 diabetes
- No access to semaglutide via drug coverage
- Pregnant, breastfeeding or planning to become pregnant
- Currently in a GLP-1RA or GLP-1RA/GIP study or planning to be in one
The study team makes the final eligibility decision.
Where it is enrolling
- London, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 26 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at London, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.